Viral vectors

Home
Immunoassays
Modalities
Viral Vectors

Viral vector analysis with the Gyrolab immunoassay platform

Viral vectors are central to the development of modern cell and gene therapies, enabling the delivery of therapeutic genes to target cells. As these therapies move rapidly from discovery to clinical application, reliable analytical methods are essential to characterize vector performance, monitor biological responses, and ensure product quality.

The Gyrolab automated immunoassay platform supports viral vector research and development by enabling highly sensitive and reproducible immunoassays with minimal sample consumption. Its automated microfluidic technology allows researchers to generate consistent data while accelerating assay workflows—supporting both early research and regulated development environments.

Powering cell and gene therapy breakthroughs

The Gyrolab platform is designed to support the demanding analytical needs of viral vector development and cell and gene therapy programs. By combining microfluidic technology with fully automated immunoassays, the system enables fast, precise, and scalable analysis of critical biomarkers and therapeutic components.

Researchers benefit from streamlined workflows, reduced assay variability, and the ability to process multiple samples efficiently—helping accelerate progress from discovery to clinical development.

The Gyrolab platform provided improved sensitivity, precision, and parallelism compared to alternative methods, enabling faster development of assays for complex transgene products."

Principal Scientist | Biopharma company

The Gyrolab system improves assay consistency and throughput for therapeutic research compared to plate-based ELISA.

Principal Scientist | Biopharma company

The main benefits of the Gyrolab^® Anti-AAVX Kit are reduced method development and reduced use of precious capsid.

The advantage of the Gyrolab^® Anti-AAVX Kit is that it’s plug-and-play so you can use your specific serotype and drug. You do not have to label the drug, and it is much easier to compare the immunogenicity of a generic serotype capsid to the drug.

Bayer logo